Shanghai Pharmaceuticals Holding Co Ltd banner
Financial profile · Q3 FY2026

A distribution-led healthcare group with steady sales and working-capital-sensitive cash generation

Across the reported years, Shanghai Pharmaceuticals has expanded revenue steadily, but its wholesale-heavy mix leaves operating margins narrow. It generates positive free cash flow with limited fixed-asset spending, while working-capital requirements make quarterly cash conversion uneven.

What is developing

The latest quarter extended modest sales growth while operating profitability improved, but this does not yet establish a durable change in the financial model. Cash conversion remains sensitive to working capital, and trailing net income has not matched the recent operating-income improvement.

What matters next

Whether operating-margin gains persist while working-capital outflows moderate enough to sustain cash conversion.

CNY
Metric FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
(3.6B) (3.7B) (5.6B) (5.6B) (5.8B) (6.2B) (8.9B) (9.8B) (10.5B) (11.2B)
(9.6B) (10.5B) (15.3B) (16.4B) (17.1B) (18.4B) (17.5B) (16.6B) (16.7B) (15.9B)
1.9B 2.6B 3.1B 6B 6.8B 5.1B 4.7B 5.2B 5.8B 6.2B
(2.1B) (2B) (1.9B) (2.8B) (3B) (4.1B) (2.7B) (3B) (2.4B) (2.3B)
(770.3m) (347.8m) (5.7B) (1.8B) 1.3B (1.9B) (9.8B) 478.7m 2.8B (1.7B)
(2.9B) (2.4B) (7.7B) (4.6B) (1.7B) (6B) (12.5B) (2.5B) 416m (4B)
— — — — — — — — 86.2m —
1.7B 3.9B 10.4B 1.7B 1.7B 4.3B 3.8B 6.9B 3.8B (891.8m)
(1.7B) (2B) (2.7B) (2.6B) (2.4B) (2.7B) (3.1B) (4B) (3.6B) (2.8B)
669.2m 473.6m (193.7m) (1.4B) (532.3m) (90.6m) 11.4B (2.6B) (2.2B) (2B)
647.4m 2.3B 7.5B (2.3B) (1.3B) 1.6B 12.1B 231.9m (1.9B) (5.7B)
(2.6m) (18.8m) 67.4m (1.6m) (17.6m) (50.3m) (12.4m) (5.6m) 2.2m (3.1m)
(298m) 2.6B 3B (889.3m) 3.9B 561.1m 4.4B 3B 4.4B (3.5B)
(172.6m) 641.5m 1.2B 3.3B 3.8B 942.6m 2.1B 2.3B 3.4B 3.8B